Evidence map›Paper›PMID 41444687›Full record

ReviewBiomarker research2025

Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches.

Tianyu Zheng, Xinran Yu, Caihong Yu, Wangting Xu, Zhuoyang Fan, Yongjie Zhou, Changyu Li, Juncheng Wan, Chaoqiao Jin, Xuran Jin and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tianyu Zheng *Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Xinran Yu *The Second Clinical College of China Medical University, Shenyang, 110122, China.
Caihong Yu *Department of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Wangting XuDepartment of Pulmonary and Critical Care Medicine, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
Zhuoyang FanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Yongjie ZhouDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Changyu LiDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Juncheng WanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Chaoqiao JinDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Xuran JinDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Wen ZhangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Zhiping YanDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China.
Peng LuoDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China. luopeng@smu.edu.cn.
Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China. tangbufu@zju.edu.cn.
Xudong QuDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, 200032, China. quxudong@fudan.edu.cn.

Funding

National Key Research and Development Program of China 2023YFC2411404Shanghai Innovative Medical Devices and Pharmaceuticals Application Demonstration Project 24SF1905500Shanghai Innovative Medical Devices Application Demonstration Project 23SHS03900-09
6 · The paper itself

Abstract

The tumor microenvironment (TME) is a key factor influencing carcinogenesis, disease progression, and therapeutic outcomes. Tumor-associated endothelial cells (TECs), integral components of the TME, form the structural and functional foundation of the vasculature, while also modulating tumor immune responses. TECs regulate immune cell activity and distribution through multiple molecular mechanisms, thereby influencing tumor immunity. Recent evidence highlights TEC-targeted interventions as a promising strategy to enhance immunotherapy efficacy. This review examines the mechanisms through which TECs drive tumorigenesis, progression, and metastasis, and explores the therapeutic potential of TEC-targeted approaches in cancer treatment. It also provides a systematic analysis of TECs’ impact on the immune microenvironment, assessing the potential of TEC-directed therapies to overcome chemoresistance and immunotherapy resistance, thus offering new perspectives for drug development targeting TECs. Finally, the review critically evaluates potential molecular targets within TECs and recent advancements in genetic research for cancer therapy, emphasizing key research priorities and pressing clinical challenges that require urgent focus.

Indexed as

Endothelial heterogeneityImmunosuppressive mechanismsTEC-targeted therapeuticsTumor-associated endothelial cells (TECs)Tumor microenvironment (TME)

Identifiers

PMID41444687
PMCPMC12784535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.